Table 1. Demographics, baseline clinical parameters and pharmacological treatment of the two groups of patients.
| SRs (59) | Non-SRs (142) | Total (201) | P value | |
| Demographic | ||||
| Male gender | 34 (57.6%) | 95 (66.9%) | 129 (64.2%) | 0.212 |
| Age, yrs | 58.8 ± 10.6 | 57.3 ± 11.4 | 57.7 ± 11.2 | 0.390 |
| Etiology | ||||
| NICM | 53 (89.8%) | 126 (88.7%) | 179 (89.1%) | 0.820 |
| ICM | 6 (10.2%) | 16 (11.3%) | 22 (10.9%) | |
| NYHA Class | ||||
| II | 17 (28.8%) | 33 (23.2%) | 50 (24.9%) | 0.206 |
| III | 38 (64.4%) | 83 (58.5%) | 121 (60.2%) | 0.170 |
| IV | 4 (6.8%) | 26 (18.3%) | 30 (14.9%) | 0.037 |
| UCG and ECG variables | ||||
| LVEF, % | 32.2 ± 8.5 | 27.4 ± 7.3 | 28.8 ± 8.3 | < 0.001 |
| LVESV, mL | 156.5 ± 49.7 | 205.0 ± 74.5 | 190.6 ± 71.6 | < 0.001 |
| LVEDV, mL | 228.4 ± 58.9 | 278.3 ± 85.1 | 263.7 ± 81.4 | < 0.001 |
| LAD, mm | 41.3 ± 7.1 | 44.8 ± 7.0 | 43.7 ± 7.2 | 0.002 |
| FMR | 1.3 ± 0.8 | 1.6 ± 0.8 | 1.5 ± 0.8 | 0.046 |
| QRS duration, ms | 164.5 ± 16.0 | 161.5 ± 19.3 | 162.4 ± 18.4 | 0.289 |
| LBBB | 56 (94.9%) | 127 (89.4%) | 183 (91.0%) | 0.215 |
| De novo | 55 (93.2%) | 138 (97.2%) | 193 (96.1%) | 0.191 |
| CRT-D | 32 (54.2%) | 80 (56.3%) | 112 (55.7%) | 0.636 |
| Co-morbidity | ||||
| Chronic AF | 9 (15.3%) | 19 (13.4%) | 28 (13.9%) | 0.727 |
| Hypertension | 19 (32.2%) | 35 (24.6%) | 54 (26.9%) | 0.456 |
| Diabetes mellitus | 9 (15.3%) | 31 (21.8%) | 40 (19.9%) | 0.285 |
| Medication | ||||
| Diuretics | 56 (94.9%) | 141 (99.3%) | 197 (98.0%) | 0.077 |
| ACEI/ARB | 52 (88.1%) | 98 (69.0%) | 150 (74.6%) | 0.005 |
| β-Blockers | 55 (93.2%) | 139 (97.9%) | 194 (96.5%) | 0.100 |
| Nitrates | 20 (33.9%) | 44 (31.0%) | 64 (31.8%) | 0.686 |
| Class III | 11 (18.6%) | 29 (20.4%) | 40 (19.9%) | 0.774 |
| Antiarrhythmics | ||||
| Spironolactone | 56 (94.9%) | 130 (91.5%) | 186 (92.5%) | 0.408 |
| Digoxin | 9 (15.9%) | 30 (21.2%) | 39 (19.4%) | 0.511 |
| Anticoagulants | 7 (11.9%) | 12 (8.5%) | 39 (9.5%) | 0.221 |
Data given as n (%) or mean ± SD. AF: atrial fibrillation; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CRT-D: cardiac resynchronization therapy-defibrillator; ECG: electrocardiographic; FMR: functional mitral regurgitation; ICM: ischemic cardiomyopathy; LAD: left atrial diameter; LBBB: left bundle branch block; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume; NICM: non-ischemic cardiomyopathy; NYHA class: New York Heart Association functional class; Non-SRs: non-super responders; SRs: super-responders; UCG: ultrasonic cardiogram.